| INTRODUCTION
Prostate cancer (PCa) accounts for over 160 000 new cases of cancer each year and constitutes the most frequent cancer diagnosis for men. 1 Despite advances in clinical, surgical, chemotherapeutic, and imaging modalities, nearly 30 000 men die each year from aggressive prostate tumors. 1 However, overdiagnosis of PCa has led to unnecessary treatment of indolent or low risk tumors that were unlikely to progress and require intervention in the patient's lifetime. [2] [3] [4] Thus, the major challenges in PCa management today are two-fold:
first, how to screen for PCa, and, second, how to treat patients once the diagnosis is made. The use of biomarkers to manage PCa has revolutionized practice, from early use of prostatic acid phosphatase (PAP) levels to prostate-specific antigen (PSA) more recently. 5 Unfortunately, PSA has a poor specificity for discriminating between cancer and other prostate conditions, including benign prostatic hyperplasia (BPH), inflammation, and infection. [5] [6] [7] In fact, the US Preventative Service Task Force has recommended against the routine use of PSA tests to screen for PCa due to concern for overdiagnosis and overtreatment. 8 Thus, there is a growing need to identify highspecificity biomarkers to correctly classify cancer disposition and predict cancer progression. Improvements in early diagnosis and classification of PCa will not only guide initial therapies, but should also inform approaches to follow and monitor patients with PCa, particularly given the wide heterogeneity in outcomes for this disease.
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The Prostate and Breast Overexpressed 1 (PBOV1) gene, also known as UROC28 or UC28, was identified as a potential biomarker to characterize PCa. First reported in 2000 by An et al 12 PBOV1 is located on chromosome 6 and encodes a 135-amino acid protein from two alternatively spliced mRNA transcripts, which differ only at the 3′ untranslated region. Although the role of the PBOV1 protein remains uncharacterized, previous experiments reveal protein localization to both the cytoplasm and the nucleus. 12 Significantly higher levels of PBOV1 mRNA transcripts were detected in the serum of patients with PCa compared to individuals without PCa and those with BPH, suggesting a role as a tumor biomarker. 12 Increased copy numbers of PBOV1 detected by in situ hybridization were reported in archival prostate tumor samples compared to benign prostate epithelium and high-grade prostatic intraepithelial neoplasia (PIN). 13 A subsequent study provided possible mechanistic insights, showing that forced overexpression of PBOV1 in cultured cell lines promoted increased cell proliferation rates and cell cycle progression from the G 1 to S phase. 14 While these results implicate PBOV1 in tumor proliferation, other studies found that phenotypes associated with PBOV1 are context dependent and vary with cell type or tissue. For example, high expression of PBOV1 correlated positively with relapse-free survival outcomes in breast cancer and glioma in a study based on clinically annotated public microarray data. 15 These results suggested possible suggesting that gene expression is hormone-dependent. 12, 17 To date, the role of the PBOV1 protein in PCa remains poorly understood. Thus, the aim of this study was to investigate the PBOV1 protein as a potential PCa biomarker. First, immunoblotting studies were performed to assess protein levels in radical prostatectomy samples. We subsequently performed an immunohistochemical and digital image analysis of the PBOV1 protein for the following reasons:
( 
| Optimization of Western blot antibodies and methods
Western blot antibody dilutions and methodology were optimized using PC3 epithelial (PC3-Epi) and PC3 epithelial-to-mesenchymal transition (PC3-EMT) PCa cell lines. This was performed to ensure that the anti-PBOV1 antibody used in this study was identifying the proper protein.
Proteins were extracted using previously described methods. 20 The PBOV1 antibody used in this study was validated as previously described 12 and recognizes epitope B of the PBOV1 protein (amino acids [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] were classified as Grade Groups 4 and 5 (GS ≥ 8) (refer to Table 2 ).
Additionally, measures of antibody staining intensity were used to estimate protein content as previously described 24 and these measures are shown in Table 3 as parameters 18-22. Parameters of staining intensity were measured by the ImagePro Premier 9.1 software (Media Cybernetics, Rockville, MD). staining intensity, including nuclear area, boundary definition, and maximum staining intensity, among others (Table 3) , were determined and recorded. Because the PBOV1 protein was previously localized to the nucleus, we assessed correlation between measures of PBOV1 staining intensity and nuclear structural changes. We then generated an to estimate the accuracy of the model and prevent data overfitting. 25 Cores were distributed to either the training set or the test set using stratified sampling methods. Cores were first stratified by Grade Group and subsequently randomly selected for either the training or test set to ensure that the proportion of Grade Groups was maintained across the training and test sets. Thus, cores in the test set were not used in the creation of the training set model. The MLR model employs a binary classification system with Grade Group 3 and above PCa as the parameter of interest for prediction based on nuclear structural parameters and PBOV1 staining intensity measures. The cancer cores from Grade Group 1 and 2 regions, the benign cores from Grade Group 1 and 2 adjacent regions, and the benign cores from Grade Group 3 and above adjacent regions were grouped together as the other binary variable.
| Digital histomorphometric image analysis with

| Statistical analysis
Mann-Whitney U test was used to evaluate the difference in the mean age and PSA levels between Grade Groups 1 and 2 and Grade Groups 3
and above PCa samples obtained from radical prostatectomy, as these data were not normally distributed. Additionally, Mann-Whitney U test was used to evaluate the difference in protein levels between Grade Groups 1 and 2 and Grade Groups 3 and above PCa cases and to assess differences in predicted probability plots derived from MLR models.
Correlations of PBOV1 staining intensity with measures of nuclear structural changes were evaluated using Spearman's rank correlation coefficients. GraphPad Prism 7 was used to generate scatter plots of the PBOV1 protein levels and the predictive probability plots. STATA 13.0 (StataCorp LLC, College Station, TX) was used for all statistical modeling and analysis. Backward stepwise logistic regression was used to create the MLR models for differentiation of cancer and benign cancer-adjacent regions with a parameter inclusion criteria of P z ≤ 0.10. Statistical significance was defined as P < 0.05. Based on these results, a univariate logistic regression model was created using protein level data from both cancer and benign regions to determine whether protein levels from immunoblotting alone could discriminate high Grade Group PCa. This model was able to distinguish Grade Group 3 and above cancer from both Grade Group 1 and 2
cancer and benign regions with a ROC-AUC of 0.75 (Sensitivity = 66.67% and Specificity = 67.85% at probability cutoff 0.24, P < 0.0001) ( Figure 4A ). In contrast, prediction of Grade Group 3 and above cancer against Grade Group 1 and 2 cancer regions only yielded a ROC-AUC of 0.86 (Sensitivity = 75.00% and Specificity = 75.00% at probability cutoff 0.45, P < 0.0001) ( Figure 4C ).
| Characteristics of TMA samples and generation of MLR models
Of the 80 unique PCa patient samples in the TMAs, 30 were classified as Grade Group 1 and 2 PCa and 50 were classified as Grade Group 3 and above. 
| PBOV1 protein in TMAs correlates with nuclear alterations in Grade Group 3 and above PCa
Images of the TMA cores revealed that the PBOV1 protein could be detected in both cancerous as well as in benign epithelial regions in FIGURE 3 PBOV1 protein levels from cancer (CA) regions only grouped by Grade Group (GG). *P < 0.05
Univariate logistic regression using PBOV1 protein levels data from Western blot to predict PCa aggressiveness. Due to the small sample size of the tissues obtained from radical prostatectomy, no test set was used in this analysis and all samples were included in the univariate model. A, Uses data from Grade Group 3 and above cancer regions versus Grade Group 1 and 2 cancer regions, benign Grade Group 1 and 2 cancer-adjacent, and benign Grade Group 3 and above cancer-adjacent regions to predict high Grade Group PCa. ROC-AUC = 0.75; Sensitivity = 66.67% and Specificity = 67.85% at Probability Cutoff 0.24. B, Predicted probability of each case in the ROC curve from A. *P < 0.0001. C, Uses only data from Grade Group 1 and 2 cancer versus Grade Group 3 and above cancer regions to predict high Grade Group PCa. ROC-AUC = 0.86; Sensitivity = 75.00% and Specificity = 75.00% at Probability Cutoff 0.45. D, Predicted probability of each case in the ROC curve from C. *P < 0.0001. Key: GG 1 and 2 CA = cancer tissue from Grade Group 1 and 2 cancer area; GG 1 and 2 B = benign tissue from matched Grade Group 1 and 2 cancer-adjacent area; GG 3 and Above CA = cancer tissue from Grade Group 3 and above cancer area; GG 3 and Above B = benign tissue from matched Grade Group 3 and above cancer-adjacent area both the nuclei and cytoplasm ( Figure 5 ). From the group of measurements available to determine staining intensity in Table 3 , Integrated Optical Density (OD) was identified as the optimal and most detailed measurement of PBOV1 staining intensity due to identification of staining luminance over a given pixel area. There was a trend for
Integrated OD levels to be higher in Grade Group 3 and above PCa regions compared to Grade Group 1 and 2 regions (P = 0.050) ( Figure 6 ) and a similar trend was observed in the protein levels assessed by immunoblotting in Figure 2 . These results also indicate that PBOV1
protein levels are present in epithelial cells since stromal cells were excluded from the digital image analysis.
In the training set, MLR analysis then revealed that eight parameters describing both PBOV1 staining intensity and nuclear architecture met inclusion criteria of P z < 0.10 as multivariate predictors of the Grade Group 3 and above PCa phenotype, including:
area (P = 0.005), area polygonal uncalibrated (P = 0.006), maximum intensity (P = 0.018), mean intensity (P = 0.019), axis minor (P = 0.062), intensity standard deviation (P = 0.019), mean diameters array (P = 0.027), and maximum diameter (P = 0.033) ( Figure 7A ). This training model yielded an AUC = 0.90 ( Figure 7B ). At a probability threshold of 0.34 for the predicted probability, the model provided a sensitivity of 82.05% and a specificity of 82.35% in distinguishing
Grade Group 3 and above PCa. In Figure 7C , a scatter plot for the training set cases showed significant differences between predicted probabilities of the samples included in the model (P < 0.0001). Next, 
| PBOV1: Original discovery and current study summary
The Prostate and Breast Overexpressed 1 (PBOV1; formerly UROC28
and UC28) was first reported by the Veltri group as a gene overexpressed in prostate, breast, and bladder cancer in 2000. 12 In | 555
comparison to non-malignant prostate and BPH tissues, PBOV1 was overexpressed by three-fold in PCa with GS 6, 7, and 8. 12 Moreover, more than a four-fold increase in PBOV1 expression was observed in metastatic PCa. 12 Based on these exciting results, the PBOV1 mRNA and protein have emerged as potential diagnostic tools and therapeutic targets for PCa. Here, we examined PBOV1 protein levels in human prostate tissues of varying Grade Groups obtained from radical prostatectomy samples. We substantiate the immunoblotting results using immunohistochemical analysis, assess correlations between PBOV1 staining intensity and nuclear architectural changes, and generate a MLR model to discriminate Grade Group 3 and above PCa based on measures of PBOV1 staining intensity and nuclear architectural changes. This study also provides a framework for a broader application of digital histomorphometric image analysis to serve as a tool to identify nuclear changes associated with a wide variety of cancer types and biomarkers to predict cancer progression.
Our results from both Western blot and digital histomorphometric image analysis show potential for PBOV1 as a clinical biomarker to distinguish higher Grade Group PCa from lower Grade Group PCa.
| Review of our findings with recent publications
In the current study, we used immunoblotting to determine protein levels from a diverse set of prostate cancer and benign patient samples from all Grade Groups. Grade Group 3 and above PCa from the surrounding normal tissue.
We also found significant correlations between PBOV1 proteins and descriptors of nuclear size and shape, particularly nuclei diameter, area, and minor axis, which were included in the MLR model as significant predictors of the Grade Group 3 and above phenotype. In the original report describing the discovery of PBOV1, An et al 12 Localized the PBOV1 protein to the cell membrane. In the current study, the protein was identified in both the cytoplasm and the nucleus, suggesting that PBOV1 is involved in diverse cellular processes.
Alterations in the nuclear architecture are some of the most important features that distinguish a cancer cell from a normal cell. 37 These structural changes could be orchestrated by the nuclear matrix and its associated proteins, which help to connect to the nuclear envelope and lamina and ultimately to the cytoskeleton. 38 Therefore, the nuclear matrix can influence nuclear size, induce deformities to nuclear shape, and alter three-dimensional nuclear organization. 38 Thus, based on the close associations observed in this study between PBOV1 proteins and changes in nuclear size and shape, we postulate that PBOV1 could alter nuclear structure either directly or indirectly. If localized primarily in the nucleus, PBOV1 could disrupt cell cycle regulation, as indicated by Pan et al, 14 thus leading to direct effects on nuclear size based on cell cycle phase and DNA replicative state.
Additionally, indirect effects could also occur through cytoskeletal changes, external changes to the extracellular matrix, or through changes to nucleocytoplasmic transport, all of which could involve the PBOV1 protein based on its cytoplasmic or cell membrane localization. Subsequent connections to the nuclear matrix could then influence nuclear structure. Further studies to determine the role of PBOV1 in the nucleus, cytoplasm, and cell membrane are needed as well as studies to elucidate its function during malignant transformation.
| Limitations of the current study
Our study was limited by sample sizes and the retrospective nature of analysis, both with respect to the radical prostatectomy patient samples as well as the TMAs, which limit broad conclusions and models. In addition, a limitation of MLR modeling is data overfitting, where the same data used to generate the training model is subsequently included in the determination of the predictive ability of the model. 25 This creates overly optimistic estimates of the MLR predictive power. 25 We attempted to address this limitation by including a training set that was validated with a test set. The test set included randomized samples that were representative of the Grade 
| Future work and potential PBOV1 biomarker pathway
While our results suggest that PBOV1 is a useful biomarker in PCa, larger sample sizes are needed to ascertain PBOV1 protein profiles in normal and cancerous tissues of all Grade Groups. Moreover, further validation of the MLR model is warranted in larger, independent populations. Additional experiments to elucidate the potential role of PBOV1 in modulating nuclear architecture could provide mechanistic insight relevant to PBOV1 tumor progression.
As PBOV1 is still in an early discovery phase as a potential PCa biomarker, 39 Longitudinal analyses comparing prediction of PCa progression using PBOV1 in comparison to PSA and GS to further assess its utility as a biomarker. Although we found a strong relationship between elevated protein levels and nuclear structural changes in higher grade PCa, further studies are needed to examine whether PBOV1 has a higher prognostic predictive value above the current GS classification system.
While GS is an important histopathological indicator of PCa prognosis, tumors with similar scores have varying clinical outcomes, making predictions of aggressiveness using GS inaccurate. 
